ABIVAX, a French company, is progressing nicely on their clinical trials of ABX464, a small molecule drug that inhibits the replication of HIV. The medicine targets the gut, which is the major reservoir of HIV in the body. This is being developed as a "functional cure" to prevent rebound of the virus from reservoirs once anti-retroviral therapies stop.
Their current trial data revealed that the vaccine has a strong anti-inflammatory effect in the gut by stimulating a significant increase of the cytokine IL-22 in macrophages.
IL-22 induces antimicrobial molecules and proliferative and antiapoptotic pathways that help prevent tissue damage and aid in its repair. These processes play a beneficial role in IBD by enhancing intestinal barrier integrity and epithelial innate immunity.
This reminds me of reports last month that Entyvio being a functional cure for AIDS in monkey experiments.
Their current trial data revealed that the vaccine has a strong anti-inflammatory effect in the gut by stimulating a significant increase of the cytokine IL-22 in macrophages.
IL-22 induces antimicrobial molecules and proliferative and antiapoptotic pathways that help prevent tissue damage and aid in its repair. These processes play a beneficial role in IBD by enhancing intestinal barrier integrity and epithelial innate immunity.
This reminds me of reports last month that Entyvio being a functional cure for AIDS in monkey experiments.